[Principles of hormone replacement therapy in climacteric].
With age-specific diminished and excluded ovarian function and estrogen deficiency, 60% of females may develop various systemic disorders (the menopausal syndrome, urogenital and cardiovascular diseases, osteoporosis). In the past 10-15 years, hormone replacement treatment regimens have been developed for climacteric females. Numerous epidemiological surveys have indicated that hormone replacement therapy shows a 50% reduction in the incidence of stroke, myocardial infarction, bone fractures. Therefore, post-menopausal hormone therapy is indicated both for therapeutical and prophylactic purposes, which may increase female longevity.
Smetnik
V P
VP
D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002979:Climacteric / Q000502:physiology; D004958:Estradiol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004964:Estriol / Q000031:analogs & derivatives / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D052776:Female Urogenital Diseases / Q000517:prevention & control; D006801:Humans; D008017:Life Expectancy; D008875:Middle Aged; D010024:Osteoporosis / Q000517:prevention & control; D011372:Progestins / Q000627:therapeutic use
D004966:Estrogens, Conjugated (USP); D011372:Progestins; D004958:Estradiol; C009341:estriol succinate; D004964:Estriol